Record-Breaking Price Movement
On 19 December 2025, Shukra Pharmaceuticals touched an intraday peak of Rs. 65.26, representing a gain of 4.99% for the day. This price level marks the highest ever recorded for the stock, underscoring a period of strong upward movement. The stock opened with a gap up, signalling positive market sentiment from the outset of trading.
The stock’s performance today notably outperformed its sector peers by 4.81%, while the broader Sensex index registered a more modest advance of 0.53%. This divergence highlights Shukra Pharmaceuticals’ relative strength within the Pharmaceuticals & Biotechnology sector on the trading day.
Consistent Gains Over Time
Shukra Pharmaceuticals has exhibited a remarkable run of consecutive gains, extending over the last 12 trading sessions. During this period, the stock has delivered returns of approximately 70.1%, reflecting sustained buying interest and positive price momentum. This streak of gains is a key contributor to the stock’s current all-time high valuation.
Further analysis of the stock’s moving averages reveals that it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment across multiple timeframes indicates a strong upward trend and a broad-based price strength that has been maintained over both short and long-term horizons.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Comparative Performance Against Benchmarks
When viewed against the Sensex, Shukra Pharmaceuticals’ returns over various timeframes illustrate a pronounced outperformance. Over the past week, the stock has recorded a gain of 27.56%, contrasting with the Sensex’s decline of 0.40%. The one-month period shows a 53.30% rise for the stock, while the Sensex experienced a slight fall of 0.30%.
Extending the horizon, the stock’s three-month performance stands at 108.83%, significantly ahead of the Sensex’s 2.79% increase. Over the course of one year, Shukra Pharmaceuticals has delivered a substantial 573.20% return, compared to the Sensex’s 7.21%. Year-to-date figures also reflect a strong 378.55% gain for the stock, while the Sensex has advanced by 8.69%.
Long-Term Growth Trajectory
Examining the stock’s longer-term performance reveals extraordinary growth. Over three years, Shukra Pharmaceuticals has appreciated by 9404.95%, dwarfing the Sensex’s 37.41% increase. The five-year return is even more striking at 25788.74%, compared with the Sensex’s 80.85%. Over a decade, the stock has recorded a gain of 17760.65%, while the Sensex has risen by 232.80% during the same period.
This sustained upward trajectory highlights the company’s ability to maintain growth and value creation over extended periods, positioning it as a notable performer within the Pharmaceuticals & Biotechnology sector.
Holding Shukra Pharmaceuticals from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector and Market Capitalisation Context
Shukra Pharmaceuticals operates within the Pharmaceuticals & Biotechnology industry, a sector characterised by innovation and evolving market dynamics. The company’s market capitalisation grade is noted as 4, reflecting its standing within the mid-to-large cap segment of the market.
The stock’s ability to outperform its sector and broader market indices over multiple timeframes suggests a strong positioning relative to peers. Its current trading levels above all key moving averages further reinforce the strength of its price trend.
Summary of Recent Market Activity
Today’s trading session saw Shukra Pharmaceuticals open with a gain of 4.99%, maintaining this momentum throughout the day to reach its new peak. The stock’s 12-day consecutive gain streak and significant returns over short and long-term periods illustrate a sustained positive market response.
While the broader market has experienced more modest movements, Shukra Pharmaceuticals’ performance stands out as a key highlight within the Pharmaceuticals & Biotechnology sector.
Conclusion
Shukra Pharmaceuticals’ achievement of an all-time high at Rs. 65.26 marks a noteworthy milestone in its market journey. The stock’s consistent gains, strong relative performance against benchmarks, and favourable technical indicators collectively underscore its robust market presence. This milestone reflects the company’s sustained growth and resilience within a competitive sector.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →
